| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 17,410 | |||
| General and administrative | 10,081 | |||
| Total operating expenses | 27,491 | |||
| Loss from operations | -27,491 | |||
| Other income (expense), net | -8 | |||
| Interest income, net | 836 | |||
| Total other income, net | 828 | |||
| Net loss | -26,663 | |||
| Net loss per share attributable to common stockholders, basic | -0.56 | |||
| Net loss per share attributable to common stockholders, diluted | -0.56 | |||
| Weighted-average common shares outstanding, basic | 47,619,724 | |||
| Weighted-average common shares outstanding, diluted | 47,619,724 | |||
Vigil Neuroscience, Inc. (VIGL)
Vigil Neuroscience, Inc. (VIGL)